Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression.
OX40L
biomarker
breast cancer
immunotherapy
platelets
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
04
2022
accepted:
08
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
In conventional T cells, OX40 has been identified as a major costimulating receptor augmenting survival and clonal expansion of effector and memory T cell populations. In regulatory T cells, (Treg) OX40 signaling suppresses cellular activity and differentiation. However, clinical trials investigating OX40 agonists to enhance anti-tumor immunity, showed only limited success so far. Here we show that platelets from breast cancer patients express relevant levels of OX40L and platelet OX40L (pOX40L) inversely correlates with platelet-expressed immune checkpoint molecules GITRL (pGITRL) and TACI (pTACI). While high expression of pOX40L correlates with T and NK cell activation, elevated pOX40L levels identify patients with higher tumor grades, the occurrence of metastases, and shorter recurrence-free survival (RFS). Of note,
Identifiants
pubmed: 35875148
doi: 10.3389/fonc.2022.917834
pmc: PMC9304936
doi:
Types de publication
Journal Article
Langues
eng
Pagination
917834Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 Rittig, Lutz, Clar, Zhou, Kropp, Koch, Hartkopf, Hinterleitner, Zender, Salih, Maurer and Hinterleitner.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncoimmunology. 2017 Nov 27;7(2):e1364827
pubmed: 29308299
Clin Cancer Res. 2021 Jan 15;27(2):460-472
pubmed: 33148673
Clin Rev Allergy Immunol. 2016 Jun;50(3):312-32
pubmed: 26215166
Cancer Manag Res. 2019 Apr 26;11:3611-3619
pubmed: 31118783
Front Oncol. 2021 Mar 17;11:642170
pubmed: 33816291
Diagnostics (Basel). 2021 Jun 30;11(7):
pubmed: 34208863
BMC Cancer. 2020 May 19;20(1):445
pubmed: 32429929
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936
PLoS One. 2015 Jul 24;10(7):e0133830
pubmed: 26207909
Blood. 2008 Nov 1;112(9):3735-43
pubmed: 18689545
Front Immunol. 2019 Feb 19;10:262
pubmed: 30838001
Nat Rev Cancer. 2011 Feb;11(2):123-34
pubmed: 21258396
Mediators Inflamm. 2019 Apr 17;2019:9213074
pubmed: 31148950
Annu Rev Immunol. 2010;28:57-78
pubmed: 20307208
J Hematol Oncol. 2018 Mar 15;11(1):39
pubmed: 29544515
Blood Coagul Fibrinolysis. 2002 Sep;13(6):505-12
pubmed: 12192302
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Blood. 2009 Mar 12;113(11):2451-60
pubmed: 19029446
Curr Opin Immunol. 2021 Aug;71:75-80
pubmed: 34182216
Oncol Rep. 2012 Aug;28(2):615-21
pubmed: 22614805
Clin Chim Acta. 2008 Nov;397(1-2):22-6
pubmed: 18674525
Expert Opin Ther Targets. 2018 Sep;22(9):783-797
pubmed: 30107134
J Immunol. 2006 Jul 1;177(1):234-45
pubmed: 16785519
Blood. 2018 Jan 4;131(1):39-48
pubmed: 29118006
J Immunother Cancer. 2018 Dec 18;6(1):149
pubmed: 30563566
Cancers (Basel). 2019 Feb 26;11(3):
pubmed: 30813611
Eur J Cancer. 2016 Jan;52:50-66
pubmed: 26645943
Oncoimmunology. 2014 Aug 03;3(8):e954483
pubmed: 25610748
Oncology. 2001;61 Suppl 2:67-72
pubmed: 11694790
Cancer Res. 2020 Jan 15;80(2):291-303
pubmed: 31727628
Clin Cancer Res. 2022 Jan 1;28(1):71-83
pubmed: 34615725
Blood Adv. 2020 May 12;4(9):1917-1926
pubmed: 32380537
Cancer Med. 2013 Oct;2(5):662-73
pubmed: 24403232
Nat Immunol. 2019 Sep;20(9):1220-1230
pubmed: 31285626
Gastroenterology. 2020 Jul;159(1):306-319.e12
pubmed: 32179091
J Exp Med. 2005 Nov 7;202(9):1213-23
pubmed: 16275760
Front Oncol. 2020 Jun 16;10:827
pubmed: 32612943
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Nat Rev Cancer. 2021 Jun;21(6):345-359
pubmed: 33837297
Front Immunol. 2022 Feb 03;13:825892
pubmed: 35185916
Blood. 2007 Jun 15;109(12):5242-50
pubmed: 17347408
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35110356
Mol Cancer Ther. 2020 Dec;19(12):2564-2574
pubmed: 32999045
Sci Rep. 2017 Apr 04;7:45826
pubmed: 28374824
Nat Commun. 2021 Dec 1;12(1):7005
pubmed: 34853305
Cancer Immunol Immunother. 2014 Apr;63(4):395-406
pubmed: 24514954
J Clin Invest. 2005 Jan;115(1):44-55
pubmed: 15630443
Cancer Immunol Immunother. 2021 Sep;70(9):2483-2496
pubmed: 33538861
Blood. 1973 Apr;41(4):587-98
pubmed: 4734124
Pathol Res Pract. 2010 Nov 15;206(11):735-9
pubmed: 20634005
Cancer Res. 2012 Jan 15;72(2):440-8
pubmed: 22127925